GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
2022 · Nature · 751 citations
https://doi.org/10.1038/s41586-022-04489-4
M
Maria Caterina Rotiroti
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
30
Papers
2.1K
Citations
12
h-index
12
i10-index
Maria Caterina Rotiroti is an academic researcher from Boston University. The author has contributed to research in topics: CAR-T cell therapy research & Immune Cell Function and Interaction & Virus-based gene therapy research. The author has an h-index of 12, co-authored 26 publications.
ORCID: 0000-0002-3214-1540Papers by this author
worksCAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
2021 · Nature Medicine · 545 citations
https://doi.org/10.1038/s41591-021-01436-0
Co-opting signalling molecules enables logic-gated control of CAR T cells
2023 · Nature · 261 citations
https://doi.org/10.1038/s41586-023-05778-2
Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia
2017 · Molecular Therapy · 152 citations
https://doi.org/10.1016/j.ymthe.2017.04.017
Engineering T cells with a membrane-tethered version of SLP-76 overcomes antigen-low resistance to CAR T cell therapy
2025 · Nature Cancer · 2 citations
https://doi.org/10.1038/s43018-025-01056-4
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat